NASDAQ:TLIS
Talis Biomedical Corporation Stock News
$9.14
+0.140 (+1.56%)
At Close: Apr 26, 2024
7 Small-Cap Stocks to Sell in August Before They Crash and Burn
09:02pm, Thursday, 10'th Aug 2023
Although speculative enterprises tend to draw in a loyal band of followers, certain circumstances call for decisive action, as these small-cap stocks to avoid in August confirms. Nobody wants to be th
Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
08:00am, Thursday, 03'rd Aug 2023
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accu
Talis Biomedical Corporation (TLIS) Q1 2023 Earnings Call Transcript
10:58am, Sunday, 14'th May 2023
Talis Biomedical Corporation (NASDAQ:TLIS ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Re
Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023
08:00am, Thursday, 04'th May 2023
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accur
Talis Biomedical Corporation (TLIS) CEO Rob Kelly on Q2 2022 Results - Earnings Call Transcript
03:48pm, Friday, 05'th Aug 2022
Talis Biomedical Corporation (NASDAQ:TLIS ) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor
Talis Biomedical Corporation(TLIS) CEO Rob Kelly on Q12022 Results - Earnings Call Transcript
11:08am, Sunday, 15'th May 2022
Talis Biomedical Corporation (NASDAQ:TLIS ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Emily Faucette - SVP-Corporate Communications and IR Rob Kelley - CEO Roger Mo
Talis Biomedical Corporation (TLIS) Q1 2022 Earnings Call Transcript
11:30pm, Wednesday, 11'th May 2022 The Motley Fool
TLIS earnings call for the period ending March 31, 2022.
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
02:05pm, Monday, 09'th May 2022 Zacks Investment Research
Clene Inc. (CLNN) delivered earnings and revenue surprises of -16.67% and 76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
09:25pm, Thursday, 05'th May 2022 Zacks Investment Research
MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022
12:00pm, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious
Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022
08:00am, Tuesday, 26'th Apr 2022
MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious di
Talis Biomedical stock bounces off record low after largest shareholder pulls share-sale plans
12:08pm, Monday, 25'th Apr 2022
Shares of Talis Biomedical Corp. TLIS, +2.34% bounced 1.9% in midday trading Monday, after the diagnostic testing company requested a withdrawal of a large share offering by a selling shareholder. Aft
Zai Lab, 111 top healthcare gainers; Talis Biomedical, Incannex lead losers'' pack
02:01pm, Wednesday, 16'th Mar 2022 Seeking Alpha
Zai Lab (ZLAB) +27%. 111 (YI) +26%. Talis Biomedical (TLIS) -42%. Incannex Healthcare (IXHL) -32%.
Manufacturing Bottlenecks Hit Launch Of Talis'' FDA-Approved COVID-19 Test
11:39am, Wednesday, 16'th Mar 2022 Benzinga
Talis Biomedical Corp (NASDAQ: TLIS ) said that it had not started its phased launch of the Talis One COVID-19 Test System due to challenges with manufacturing. The company has engaged in a manufacturing review process to determine appropriate next steps and initiatives to align resources and preserve cash. Talis Biomedical will cut its … Full story available on Benzinga.com